Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 4/20 | 0.33 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | ATIC | P31939 | 2/20 | 0.32 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.30 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.30 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.30 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.30 |
| ▸ | FEN1 | P39748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18048340 | 1.00 | LMNA (0.36) | LMNABRD4SYKEPAS1PDE3B | |
| SCHEMBL18067976 | 0.81 | EPAS1 (0.42) | LMNABRD4EPAS1PDE3BPDE3A | |
| SCHEMBL19858559 | 0.81 | EPAS1 (0.42) | LMNABRD4EPAS1PDE3BPDE3A | |
| SCHEMBL19870743 | 0.81 | EPAS1 (0.42) | LMNABRD4EPAS1PDE3BPDE3A | |
| SCHEMBL20315388 | 0.80 | LMNA (0.37) | LMNABRD4EPAS1ATIC | |
| SCHEMBL20163184 | 0.79 | LMNA (0.36) | LMNAPDE3BPDE3ASMARCA2SMARCA4 | |
| SCHEMBL16555720 | 0.71 | EPAS1 (0.36) | EPAS1 | |
| SCHEMBL18036903 | 0.71 | EPAS1 (0.36) | EPAS1 | |
| SCHEMBL3758819 | 0.69 | CHEK1 (0.42) | LMNABRD4SYKSMARCA2SMARCA4 | |
| SCHEMBL21362831 | 0.68 | EPAS1 (0.46) | EPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10807948-B2 | Aromatic compounds and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-10786480-B2 | Combination therapy of a HIF-2-α inhibitor and an immunotherapeutic agent and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20190282535-A1 | COMBINATION THERAPY OF A HIF-2-ALPHA INHIBITOR AND AN IMMUNOTHERAPEUTIC AGENT AND USES THEREOF | PELOTON THERAPEUTICS, INC. | 2019-09-19 | — | — | US | disclosed |
| US-10335388-B2 | Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-10278942-B2 | Compositions for use in treating pulmonary arterial hypertension | PELOTON THERAPEUTICS, INC. (US) | 2019-05-07 | — | — | US | disclosed |
| US-20190015377-A1 | Compositions for Use in Treating Pulmonary Arterial Hypertension | PELOTON THERAPEUTICS, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-20180177754-A1 | COMPOSITIONS FOR USE IN TREATING PULMONARY ARTERIAL HYPERTENSION | PELOTON THERAPEUTICS, INC. | 2018-06-28 | — | — | US | disclosed |
| US-20180162807-A1 | AROMATIC COMPOUNDS AND USES THEREOF | PELOTON THERAPEUTICS, INC. | 2018-06-14 | — | — | US | disclosed |
| US-20180042884-A1 | COMPOSITIONS FOR USE IN TREATING GLIOBLASTOMA | PELOTON THERAPEUTICS, INC. | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190282535-A1 | COMBINATION THERAPY OF A HIF-2-ALPHA INHIBITOR AND AN IMMUNOTHERAPEUTIC AGENT AND USES THEREOF | HIF1AN, HIF1A, EGLN2 | LMNA 4219/4885BRD4 1338/4885SYK 2344/4885 |
| US-20180042884-A1 | COMPOSITIONS FOR USE IN TREATING GLIOBLASTOMA | MGMT, NEFM, TUBB3 | LMNA 1126/4885BRD4 1711/4885SYK 3250/4885 |
| US-10786480-B2 | Combination therapy of a HIF-2-α inhibitor and an immunotherapeutic agent and uses thereof | HIF1AN, HIF1A, EGLN2 | LMNA 4070/4885BRD4 1125/4885SYK 2535/4885 |
| US-10278942-B2 | Compositions for use in treating pulmonary arterial hypertension | MYLK, TNNI3, PDE2A | LMNA 365/4885BRD4 2402/4885SYK 2946/4885 |
| US-20190015377-A1 | Compositions for Use in Treating Pulmonary Arterial Hypertension | MYLK, TNNI3, PDE2A | LMNA 365/4885BRD4 2402/4885SYK 2946/4885 |
| US-20180177754-A1 | COMPOSITIONS FOR USE IN TREATING PULMONARY ARTERIAL HYPERTENSION | MYLK, TNNI3, PDE2A | LMNA 365/4885BRD4 2402/4885SYK 2946/4885 |
| US-10807948-B2 | Aromatic compounds and uses thereof | VHL, HIF1AN, HIF1A | LMNA 2705/4885BRD4 497/4885SYK 3601/4885 |
| US-20180162807-A1 | AROMATIC COMPOUNDS AND USES THEREOF | HIF1A, HIF1AN, VHL | LMNA 1669/4885BRD4 322/4885SYK 3298/4885 |
| US-10335388-B2 | Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof | HIF1AN, HIF1A, EGLN2 | LMNA 4127/4885BRD4 1422/4885SYK 2585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.